BioSpace News Archive

Lentiviral vectors find utilization as a medium to make a delivery of foreign genetic material into a separate cell. Making use of a type of retrovirus, a lentivirus, these vectors are produced.

The growth of the global d-dimer testing market is ascribed to its high demand across the globe. Shortage of radiological interventions, cost effectiveness, and high accuracy is expected to bolster demand for d-dimer tests over the timeframe of analysis, from 2019 to 2029.

Seventy percent of employers have been negatively impacted by the coronavirus pandemic and more than half have implemented cost-cutting measures that affected their employees, according to Navigating the Pandemic: A Survey of U.S. Employers, a report released by nonprofit Transamerica Institute® and its Transamerica Center for Retirement Studies®.

Amsterdam, the Netherlands – Royal Philips announced that the exchange ratio for the dividend in shares for the year 2020 has been determined.

Qualtrics, the world’s No. 1 Experience Management provider and creator of the XM category, announced that Ardent Health Services, one of the industry’s most innovative healthcare systems with 30 hospitals and 25,000 employees nationwide, has chosen Qualtrics to transform and elevate the experiences of both patients and health care workers.

Company plans to activate at least 13 clinical sites for Alzheimer’s study and 18 clinical sites for head and neck cancer across the United States

Bio-Techne Corporation announced it is joining the Cell and Gene Therapy Catapult process analytical technology consortium, which includes over 20 pharmaceutical companies, technology providers, therapy developers, and charities.

EMBARK is a ground-breaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced the formation of its Clinical Advisory Committee.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that the U.S. Food and Drug Administration has granted Fast Track designation for Bemcentinib in combination with an anti-PD-1 agent for the treatment of patients with AXL-positive advanced/metastatic non-small cell lung cancer.